Cart
sales@molnova.com
Mutated EGFR-IN-1
CAS No. 1421372-66-8
Mutated EGFR-IN-1 ( Osimertinib analog )
Catalog No. M23574 CAS No. 1421372-66-8
Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 48 | In Stock |
|
| 50MG | 55 | In Stock |
|
| 100MG | 74 | In Stock |
|
| 200MG | 106 | In Stock |
|
| 500MG | 177 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMutated EGFR-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionMutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
-
DescriptionMutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
-
SynonymsOsimertinib analog
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR (L858R);EGFR (T790M);EGFR(Exon 19 deletion/T790M)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1421372-66-8
-
Formula Weight445.6
-
Molecular FormulaC25H31N7O
-
Purity>98% (HPLC)
-
SolubilityDMSO: 75 mg/mL (168.33 mM)
-
SMILESNC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Patent WO 2013014448 A2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer .
molnova catalog
related products
-
EGF816 mesylate
EGF816 (Nazartinib) is a potent, irreversible, mutant-selective EGFR inhibitor with Ki and Kinact of 31 nM and 0.222 min-1, respectively.
-
Cetuximab (anti-EGFR...
Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
FRAX597
FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).
